Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | FT596 |
Trade Name | |
Synonyms | FT-596|FT 596 |
Drug Descriptions |
FT596 consists of induced pluripotent stem cell (iPSC)-derived natural killer cells engineered to express a CD19 targeting chimeric antigen receptor (CAR), a fusion protein consisting of IL15 and IL-15R alpha, and CD16, which may lead to enhanced cytotoxicity in CD19-expressing tumor cells (Blood (2019) 134 (Supplement_1): 301). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | C170800 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cyclophosphamide + Fludarabine + FT596 | Cyclophosphamide FT596 Fludarabine | 0 | 1 |
Cyclophosphamide + Fludarabine + FT596 + Obinutuzumab | Cyclophosphamide FT596 Fludarabine Obinutuzumab | 0 | 1 |
Cyclophosphamide + Fludarabine + FT596 + Rituximab | Cyclophosphamide FT596 Fludarabine Rituximab | 0 | 1 |
FT596 | FT596 | 0 | 0 |
FT596 + Rituximab | FT596 Rituximab | 0 | 1 |